drugset / Trial / NCT00657839

Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia

NCT00657839

Phase 2 Completed 222 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

Assessment of efficacy of vardenafil in the treatment of subjects with symptomatic Benign Prostatic Hyperplasia.The purpose of this study is to find out whether vardenafil can improve the lower urinary tract symptoms of benign prostatic hyperplasia after 8 weeks of daily administration of 10 mg BID.

Timeline

Start
2005-10
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 10 mg